HOSPITAL MEDICINES LIST
RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER

Name: .....

Ward: .....

PATIENT:

Name: .....

NHI: .....

Lenvatinib

INITIATION – thyroid cancer
Re-assessment required after 6 months
Prerequisites (tick boxes where appropriate)

- ○ Patient is currently on treatment with lenvatinib and met all remaining criteria prior to commencing treatment

or

- ○ The patient has locally advanced or metastatic differentiated thyroid cancer

and

- ○ Patient must have symptomatic progressive disease prior to treatment

or

- ○ Patient must progressive disease at critical anatomical sites with a high risk of morbidity or mortality where local control cannot be achieved by other measures

and

- ○ A lesion without iodine uptake in a RAI scan

or

- ○ Receiving cumulative RAI greater than or equal to 600 mCi

or

- ○ Experiencing disease progression after a RAI treatment within 12 months

or

- ○ Experiencing disease progression after two RAI treatments administered within 12 months of each other

and

- ○ Patient has thyroid stimulating hormone (TSH) adequately supressed

and

- ○ Patient is not a candidate for radiotherapy with curative intent

and

- ○ Surgery is clinically inappropriate

and

- ○ Patient has an ECOG performance status of 0-2

CONTINUATION – thyroid cancer
Re-assessment required after 6 months
Prerequisites (tick box where appropriate)

- ○ There is no evidence of disease progression

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER

Name: .....

Ward: .....

PATIENT:

Name: .....

NHI: .....

Lenvatinib *- continued*

INITIATION – unresectable hepatocellular carcinoma
Re-assessment required after 6 months
Prerequisites (tick boxes where appropriate)

- ○ Patient has unresectable hepatocellular carcinoma

and

- ○ Patient has preserved liver function (Childs-Pugh A)

and

- ○ Transarterial chemoembolisation (TACE) is unsuitable

and

- ○ Patient has an ECOG performance status of 0-2

and

- ○ Patient has not received prior systemic therapy for their disease in the palliative setting

or

- ○ Patient has experienced treatment-limiting toxicity from treatment with atezolizumab with bevacizumab

and

- ○ No disease progression since initiation of atezolizumab with bevacizumab

CONTINUATION – unresectable hepatocellular carcinoma
Re-assessment required after 6 months
Prerequisites (tick box where appropriate)

- ○ There is no evidence of disease progression

INITIATION – renal cell carcinoma
Re-assessment required after 4 months
Prerequisites (tick boxes where appropriate)

- ○ The patient has metastatic renal cell carcinoma

and

- ○ The disease is of predominant clear-cell histology

and

- ○ The patient has documented disease progression following one previous line of treatment

and

- ○ The patient has an ECOG performance status of 0-2

and

- ○ Lenvatinib is to be used in combination with everolimus

or

- ○ Patient has received funded treatment with nivolumab for the second line treatment of metastatic renal cell carcinoma

and

- ○ Patient has experienced treatment limiting toxicity from treatment with nivolumab

and

- ○ Lenvatinib is to be used in combination with everolimus

and

- ○ There is no evidence of disease progression

CONTINUATION – renal cell carcinoma
Re-assessment required after 4 months
Prerequisites (tick box where appropriate)

- ○ There is no evidence of disease progression

I confirm that the above details are correct:

Signed: ..... Date: .....